Stable caloric intake and continued virologic suppression for HIV-positive antiretroviral treatment-experienced women after switching to a single-Tablet regimen of emtricitabine, rilpivirine, and tenofovir disoproxil fumarate
| Autor: | Cheryl Marcus, Michael G. Hudgens, John C Rublein, Joseph J. Eron, Jennifer Wills, Erin Hoffman, Zimeng Xie, Prema Menezes, Katie R. Mollan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Adult medicine.medical_specialty Tenofovir Sustained Virologic Response Anti-HIV Agents Immunology Human immunodeficiency virus (HIV) HIV Infections medicine.disease_cause Emtricitabine Antiviral Agents Maintenance Chemotherapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Virology Internal medicine Clinical Studies Antiretroviral treatment Medicine Humans 030212 general & internal medicine business.industry Rilpivirine Middle Aged Viral Load 030112 virology Caloric intake Regimen Infectious Diseases Treatment Outcome chemistry Reverse Transcriptase Inhibitors Female business Energy Intake Viral load medicine.drug Tablets |
| DOI: | 10.17615/wsfz-2165 |
| Popis: | Benefits of switching to a single-Tablet regimen (STR) of emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) in virologically suppressed antiretroviral treatment (ART) experienced HIV-positive women include pregnancy category B rating and lack of clinically significant drug interactions between RPV and oral contraceptives. Unfortunately, studies involving switching to FTC/RPV/TDF enrolled fewer than 25% women. We undertook this 48-week study to assess the ability of virologically suppressed HIV-positive women switching to RPV STR to remain virologically suppressed and comply with the caloric intake requirement. HIV-positive women on ART with viral load |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|